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Abstract 
Background: Generic preference based measures (PBM) such as the SF-6D and 
EQ-5D are increasingly used to inform health care resource allocation decisions.  
They aim to be generic in the sense of being applicable to all physical and mental 
health conditions. However, their applicability has not been demonstrated for all 
mental health conditions.   
Aims: To assess the construct validity and responsiveness of EQ-5D and SF-6D 
measures in depression and anxiety. 
Method: A systematic review of the literature was undertaken. Eleven databases 
were searched in December 2010 and reference lists scrutinised to identify relevant 
studies. Studies were appraised and data extracted. A narrative synthesis was 
performed of the evidence on construct validity including known groups validity 
(detecting a difference in PBM scores between different groups such as different 
levels of severity of depression), convergent validity (strength of association between 
generic PBM and other outcome measures) and responsiveness (the ability to detect 
relevant health changes in health status and the absence of change where there is 
none).  
Results: 26 studies were identified that provided data on the validity and/or 
responsiveness of the EQ-5D and SF-6D. Both measures demonstrate good 
construct validity and responsiveness for depression. One study, however, suggests 
EQ-5D may lack responsiveness in the elderly. These measures are more highly 
correlated with depression scales in patients with anxiety than they are clinical 
anxiety scales suggesting known group validity in patients with anxiety may be driven 
by aspects of depression within anxiety disorder and the presence of co-morbid 
depression. Direct comparisons between the measures find that the EQ-5D gives 
lower utility levels for severe depression hence greater health improvement for this 
group and SF-6D shows more sensitivity to mild depression and performs better in 
terms of ES and SRM. The comparison between EQ-5D and SF-6D is similar to that 
found in other conditions.  
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Conclusion: The evidence base supports the use of EQ-5D and SF-6D in patients 
with depression and anxiety. More work is needed on the true utility level for severe 
depression.   
 
List of abbreviations 
 ACQ 14-item self-report instrument measuring the frequency of fearful cognitions associated with panic attacks and agoraphobia (scores from 0 to 4) BAI Beck Anxiety Inventory Anxiety-specific measure of psychopathology. 21-item measure designed to assess the severity of self-reported anxiety. The total score ranges from 0 to 63, with higher scores indicating higher levels of anxiousness. Patient completed. BDI-II Beck Depression Inventory 21-item, self-report measure of severity of depression. Scored 0 to 63, with a high score indicating severe depression. Patient completed. BRMS Bech-Rafaelsen Mania Rating Scale – Modified version (BRMS). Clinician rated. BRAMES Severity of depression 11 items, rated 0-44, Clinician rated. BSQ Body Sensation Questionnaire  Anxiety-specific measure of psychopathology. 17-item self-report instrument to evaluate fear of the physical sensations generally associated with a panic attack. Patient completed. Scored 0 to 4. CES-D  Centre for Epidemiological Studies Depression Scale  20 item questionnaire on feelings of depression, scored 0-60. Patient completed CGI-S Severity of illness scale, rated 1-7. Clinician rated. CV Convergent validity DD Depressive Disorder DE Depressive Episode ES Effect size (mean assessment – mean baseline)/SD pooled SD at baseline EPDS Edinburgh Postnatal Depression Scale EQ-VAS The VAS question asked alongside the EuroQol EQ-5D measure. GAD Generalized Anxiety Disorder GAD-Q-IV   9 item diagnostic measure of GAD. Clinician rated.  
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GAF Overall occupational functioning. Clinician rated. HADS Hospital Anxiety and Depression Scale  Scored 0 (no anxiety) to 21 (many complaints of anxiety). Clinician rated. Subscales: HADS-D (depression) HADS-A (anxiety) HAM-D or HRSD Hamilton Depression Rating Scale The original scale has 17 items. Scores range 0 to 62, higher scores indicating more severe symptoms. Clinician rated. HRQL Health related quality of life KGV Known group validity MADRS Montgomery-Asberg Depression Rating Scale. Clinician rated. MBI Maslach Burnout Inventory Work related stress. 3 subscales. Patient completed. M-CIDI Munich version of Composite International Interview MDD Major Depressive Disorder MDE Major Depressive Episode MDI Major Depressive Inventory  12 items used to calculate scores on 10 ICD-10 symptoms of depression. Patient completed. MI Mobility Inventory Anxiety-specific measure of psychopathology. The MI is a 29-item self-report instrument measuring the severity of behavioural avoidance. The MI is divided into two subscales, Avoidance Alone (MIA) and Avoidance Accompanied (MIB). Patient completed. Scores range 0 to 4. NICE National Institute of Health and Clinical Excellence OLS Ordinary Least Squares PC Primary Care PHQ Patient health questionnaire Includes a 9 item depression scale PROQSY  Computerized assessment of  minor psychological morbidity based on the Clinical Interview Schedule QALY Quality adjusted life year QLDS Quality of Life in Depression Scale  34 item depression specific HRQL instrument. Scores range from 0-34, with 34 indicating worst possible case. Patient completed. Q-LES-Q-SF Quality of Life Enjoyment and Satisfaction Questionnaire – short form 15 general activity items and one overall life satisfaction 
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Sheehan disability scale – patient reported 3 item questionnaire to assess mental health functional impairment QWB Quality of Well-being.  Preference based measure of utility. R Responsiveness RCT Randomised controlled trial SCL-A Symptom Checklist 10 questions scored from 10 (no anxiety) to 50 (many complaints of anxiety). Clinician rated. SD  Standard Deviation. SCID Structure Clinical Interviews for DSM Disorders SIGH-A Structured Interview Guide for the Hamilton Anxiety Scale.  Clinician rated. SF-36 Short-form 36. Generic HRQL measure consisting of 8 dimensions assessing physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, mental health, role limitation due to emotional problems, and social functioning. Two summary scores assess physical (PCS) and mental (MCS) facets. Scores range from 0 to 100. SG Standard gamble SRMs Standardised response means. (mean at assessment – mean baseline) / SD of differences in mean scores SSI-28 Somatic Symptom Inventory  TAU Treatment as Usual TTO Time trade-off VAS Visual analogue scale VAS-pain Visual analogue scale for pain WHOQOL-BREF World Health Organization Quality of Life-Brief questionnaire. Patient completed. WHO-CIDI World Health Organisation’s 12 month Composite International Diagnostic Interview  YMRS Young mania rating scale. Clinician rated. 
 6 
INTRODUCTION 
 
Generic preference-based health status measures such as the EuroQol-5D (EQ-5D) 
are increasingly being used to inform health policy.  The last decade has seen the 
increased use of economic evaluation, particularly the use of cost effectiveness 
analyses by agencies such as NICE to inform resource allocation decisions (NICE, 
2008) where interventions are assessed in terms of their cost per Quality Adjusted 
Life Year (QALY). The QALY provides a way of measuring the benefits of health care 
interventions, including improvements in HRQL usually measured using a generic 
measure like EQ-5D. However, there has been only a limited use of generic 
measures of health in mental health (Gilbody et al, 2003).  
 
The EQ- 5D and other generic preference-based measures such as the SF-6D 
(Brazier et al, 2002) aim to be applicable to all interventions and patient groups. For 
many physical conditions these instruments have passed psychometric tests of 
reliability and validity (e.g. for rheumatoid arthritis patients (Marra et al, 2005)), but 
not all (e.g. visual impairment in macular degeneration (Espallargues et al, 2005) and 
hearing loss (Barton et al, 2004). Doubts have also been raised about the 
appropriateness of generic measures in mental health (Brazier, 2010) and whether 
they are “sufficiently sensitive to the kinds of symptoms, functioning and quality of life 
change important for people with mental health problems.” (Knapp and Mangalore, 
2007: 292).  
 
One solution would be to use disease-specific preference-based measures (PBM), 
for example, there have been attempts to derive PBM from the PANSS and CORE-
OM in mental health (Mavranezouli et al, 2011). However, there are concerns about 
the comparability of such disease specific scales and in the UK, health technology 
assessment submissions to NICE are expected to follow the details outlined in the 
‘reference case’ analysis described by the NICE methods guide (NICE, 2008). This 
clearly stipulates that wherever possible and appropriate, the EQ-5D is the favoured 
measure for generating utility values, thus allowing a common metric to assess 
health care interventions. Alternative measures may be used where the EQ-5D has 
been empirically demonstrated to be inappropriate in terms of their validity and 
responsiveness. 
 
To assess the appropriateness of generic PBM in patients with depression and 
anxiety, we have undertaken a systematic review to investigate the construct validity 
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and responsiveness of generic PBM in depression and anxiety. This forms part of a 
wider project funded by the Medical Research Council (MRC) exploring the 
appropriateness of using generic PBM for mental health.  
 
The review here will consider whether there is evidence to support the construct 
validity (or the degree to which an instrument measures what it claims to be 
measuring) and responsiveness (or the extent to which a measure can detect a 
clinically significant or practically important change over time (Walters, 2009) of 
generic utility measures within patient’s with depression and/or anxiety.  
 
METHODS 
 
Utility measures being evaluated 
 
EQ-5D 
The EQ-5D questionnaire comprises a five dimensions: mobility, self-care, usual 
activities, pain and anxiety/depression. Respondents are asked to report their level of 
problems (no problems, some/moderate problems or severe/extreme problem) on 
each dimension to provide a position on the EQ-5D health state classification. 
Responses can be converted into one of 243 different health state descriptions 
(ranging from no problems on any of the dimensions [11111] to severe problems on 
all five dimensions [33333]) which each have their own preference-based score. 
Preference-based scores are determined by eliciting preferences i.e. establishing 
which health states are preferred from a population sample. To derive preferences a 
method such as time trade off (TTO) is used which involves asking participants to 
consider the relative amounts of time (for example, number of life-years) they would 
be willing to sacrifice to avoid a certain poorer health state. Utility values for each 
state have been elicited from respondents in various countries (see 
www.Euroqol.org). The scoring algorithm, or social tariff, for the UK is based on TTO 
responses of a random sample (n=2,997) of non-institutionalised adults. Values are 
anchored by ‘1’ representing full health and ‘0’ representing the state ‘dead’ with 
states ‘worse than death’ bounded by ‘-1’. Utility values from the UK EQ-5D tariff 
range from -0.59 to 1 (Dolan, 1997). The EQ-5D is often administered with the EQ-
VAS requiring a direct valuation of the respondent’s health state on a scale from 
worst health imaginable to best imaginable. Whilst this is also a reflection of 
individual preferences (Parkin and Devlin, 2006), it is not normally used to derive 
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QALYs, in part due to concerns that the VAS scale does not explicitly involve choice, 
nor provide a cardinal measure that is needed for QALYs.  
 
SF-6D 
The SF-6D provides a means of translating the widely used general health measure 
the SF-36 (Ware and Sherbourne, 1992) or the SF-12 into a preference-based single 
index (Brazier et al, 2002).  The SF-6D reduces the eight dimensions of the SF-36 
into six: physical functioning, role limitations, social functioning, pain, mental health 
and vitality. Each dimension has 4, 5 or 6 levels, giving a total of 18,000 possible 
health states. The values attached to each level and dimension generated by the 
classification system were derived from standard gamble (SG) valuations for a 
sample of 249 of these health states. Face-to-face interviews were conducted with a 
representative sample of 611 members of the UK population (Brazier et al, 2002).  
 
Respondents initially ranked five SF-6D health states, plus the best and worst states 
from the SF-6D and immediate death. The SG questions then asked respondents to 
choose between each of five certain SF-6D states (imagining remaining in those 
states for the rest of their lives), versus a gamble between the best and ‘pits’ health 
states. Respondents were then asked to value the ‘pits’ state in relation to immediate 
death. The form of this valuation varied depending upon whether the respondent had 
ranked the ‘pits’ state as better or worse than dead. The result of the ‘pits’ valuation 
was used to ‘chain’ the health states such that they could be placed on the 0 (dead) 
to 1 (full health) scale. The valuations for the SF-6D were derived from a linear 
random effects model, and ranged from 0.29 to 1.0. (Brazier et al, 2002; Brazier et 
al., 2008).  
 
Inclusion and exclusion criteria 
Studies were eligible for inclusion if they contained data on any preference based 
health related quality of life measure within adults with depression or anxiety. This 
included studies that used a standardised utility measure within a trial setting, or as 
part of studies looking at the burden of illness of depression and anxiety. The 
outcomes had to include data that allowed measurement of the construct validity (i.e. 
known groups or convergent) or the responsiveness of the preference-based 
measure(s). Studies in which depression was not the primary diagnosis, but was co-
morbid to another condition, were excluded. Those studies which contained only the 
VAS part of the EQ-5D were also excluded.  
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Identification of studies 
For this review, 11 databases1 were searched for published research, with searches 
limited to the English Language. (Search strategies are available from the authors). 
All searches were conducted in December 2010. The reference lists of relevant 
studies were searched for further papers. Citations, and where necessary full papers, 
identified by the searching process were screened by one reviewer (TP) using the 
inclusion criteria.  
 
Data extraction  
Data from all included studies were extracted (by one reviewer (TP)) using a form 
designed specifically for the broader project, and piloted on a sample paper. Data 
extracted included: country of publication, type of disorder, study sample 
characteristics (numbers, age, gender), outcome measures used, mean values for 
utility measures, and validity and responsiveness data. Where publications reported 
on similar data, this is highlighted and only recorded where different aspects of 
analysis are conducted.  
 
Quality Assessment 
The overall quality of a study does not necessarily determine whether it can provide 
useful evidence on the validity and responsiveness of the preference-based 
measures it contains. For example, to assess effectiveness of an intervention data 
should be analysed on an intention to treat basis. However, this is not necessary to 
be able to judge whether the utility measure is responsive to a change in health. As 
there is no formal method for assessing the quality of studies for this purpose (i.e. 
there are no quality assessment checklists) we draw on the methods described by 
Fitzsimmons et al (2009) to evaluate health-related quality of life data in their 
systematic review on the use and validation of quality of life instruments within older 
cancer patients. This includes whether tests of statistical significance were applied, 
whether differences between treatment groups were reported, whether clinical 
significance was discussed and whether missing data were documented.  
 
The extent of missing data is important to know in order to judge how representative 
findings might be for patients with depression and anxiety. Missing item data and 
                                                 
1 Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, 
NHS Economics and Evaluations Database, Health Technology Database, Database of 
Abstracts of Reviews of Effects, MEDLINE, PreMEDLINE, CINAHL, EMBASE, Web of 
Science and PsycInfo. 
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completion rates for utility measures is also an important aspect of their practicality. 
However, that is not the focus of this review. How researchers have dealt with 
missing items within a scale is also important yet is not always reported. Studies may 
report that values have been imputed, although useful to know, does not in itself give 
sufficient information to assess appropriateness of how missing items have been 
dealt with. 
 
Appropriate tests of significance between groups, and for changes over time, should 
be applied and discussed. It will not be possible to make judgments overall about 
whether the utility measure can identify groups which the population or patients 
consider to have a different health state, without such tests. If particular studies lack 
significance tests, they can however, help our general understanding and contribute 
towards a broader picture. 
 
Studies should provide sufficient information to enable the reader to know exactly 
what utility measure is being used (for example, where a tariff based on public 
preferences is used this should be clearly referred to).  
 
The overall aim of this review is to see if there is an accumulation of evidence that 
does or does not support the use of utility values in depression and anxiety. If studies 
identify findings which contradict an overall picture, knowing why this is the case, will 
contribute towards our understanding. We do not want to exclude studies based on 
any strict quality criteria, unless specific information on utility scores can not be 
extracted or there is a danger of misinterpretation of the findings. 
 
Evidence synthesis and meta-analysis 
Due to the large degree of heterogeneity between studies (including types of study 
designs, outcome measures, population characteristics and methods of determining 
construct validity and responsiveness) it was not appropriate to perform meta-
analysis. Analysis was by narrative synthesis and data were tabulated.  
 
Defining validity and responsiveness 
Construct validity is defined as the extent to which an instrument measures the 
construct it is designed to measure and in the settings it is designed for (Streiner, 
2003). Support for construct validity of health measures in the psychometric literature 
is typically taken from: Firstly, showing that the measure distinguishes between 
groups which we would expect to have different levels of the construct (known group 
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validity), such as the presence or absence of a disease or different levels of disease 
severity; Secondly, showing that the measure correlates highly with alternative, 
preferably validated, measures which are designed to measure the same construct 
(convergent validity). Evidence for known group validity will come from showing 
statistically significant differences in the average utility score by subgroup of another 
outcome which may be a measure of disease severity, functioning, disease specific 
quality of life or generic quality of life. Outcome measures may be judged either by 
the clinician or patient themselves. Patient measures are usually given more weight 
when measuring quality of life. Evidence for convergent validity will come from 
showing significant, preferably high, correlation to other outcome measures. 
Regression analysis can also be used to explore whether the generic utility measure, 
(or change in that measure), is related to factors which are identifying the construct 
we are trying to pick up (e.g. disease severity) and not to external factors unrelated to 
that construct (e.g. personal characteristics). 
 
Support for the responsiveness of a measure is typically taken from showing that the 
measure responds to a change in health status, possibly following an intervention. If 
the measure changes when we expect it to, or changes in line with other measures, 
this also provides additional support for construct validity. Evidence for 
responsiveness will come from significant correlation with change scores on clinical 
outcome measures, significant change in the utility measure before and after an 
intervention and significant differences between patients classified as responders or 
non-responders by clinical or self-report measures. The performance of different 
outcome measures can be compared using effect sizes (ES) that compare the size of 
the effect or change relative to variability in the population. Common measures 
include the standardized response mean (SRM) which is computed by dividing the 
mean change in score (i.e. follow-up minus baseline) by the standard deviation of the 
change (Terwee et al, 2003) and the Cohens’ D which is calculated by dividing the 
mean change in score by the standard deviation at baseline. Effect sizes of 0.2 are 
defined as small, 0.5 defined as moderate, and 0.8 defined as large (Cohen, 1988).  
 
Traditional psychometric methods for considering construct validity and 
responsiveness need to be adapted to deal with utility scales. Generic multi-attribute 
utility scales are comprised of three elements: choice of dimensions; the levels for 
each dimension; the weights or preference attributed to each level/dimension. The 
validity and responsiveness of the first two can be assessed by traditional means 
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through considering data disaggregated into each dimension and comparing this to 
other quality of life and clinical measures. However, judging the validity and 
responsiveness of the combined utility score is less straightforward as this 
incorporates public preferences towards each state in addition to a description of the 
state, consequently, the application of these psychometric criteria to preference-
based measures requires some adaptation (Brazier and Deverill, 1999). A generic 
utility measure may fail to identify change in an aspect of health which is identified by 
a disease severity measure, but if this change is not important to patients and not 
valued by them or the general population, then this is not a weakness of the utility 
measure.  
 
For construct validity of utility measures tests of known group validity must be 
between groups which patients would report as different and the general population 
would value differently (Brazier and Devrill,1999). We would like to know if the utility 
measures can identify differences in health which society would like to take into 
consideration in resource allocation decisions.  
 
It may be possible to validate one utility measure against another. Where different 
utility measures have used different methods to generate the weights and use 
different dimensions this may be particularly useful, however, it is not clear which of 
the utility scales could be taken as a gold standard. Where differences exist between 
utility measures considering the methodology of the development process of the 
utility scale may shed light on this. For example, did the measure incorporate mental 
health in the development of the dimensions? Did those who valued the states have 
a good understanding of how different levels on a mental health dimension would 
impact upon quality of life? 
 
Measures that pick up quality of life from a patient perspective and those which focus 
on functioning, are likely to have a stronger relationship to preferences than symptom 
based, and disease severity measures. Consequently, greater emphasis will be put 
on those comparisons. 
 
Comparisons between utility scales and non-preference based quality of life scales or 
clinical measures do not necessarily support/or show lack of support for construct 
validity as they not designed to measure the same construct. However, these 
comparisons may highlight interesting differences between scales or parts of scales, 
which helps to build a picture of how useful utility measures are for this patient group.  
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For assessing responsiveness of utility measures, we require that the utility measure 
can identify a change in health where the before and after health states would be 
valued differently by the patient or the general public. Change which is not valued by 
society and/or the individual would not be expected to be picked up by a utility 
measure.  
 
Assessing health measurement scales draws on an accumulation of evidence that 
suggests converging results, rather than single experiments (Streiner and Norman, 
2003). Given the additional complexity of needing to judge utility measures by how 
closely they reflect preferences towards health states rather than just health states, 
this need for converging evidence from a number of different perspectives is even 
more important.  
 
 
FINDINGS 
 
Study characteristics 
The search identified 479 studies. On reading titles and abstracts 427 were excluded 
and 29 were excluded on reading the full paper, leaving 23 papers. Following up on 
references gave an additional 6 papers.  In some cases less commonly used 
preference-based HRQL measures were used. One study used the HUI2 and HUI3 
(Revicki et al, 2008), two studies used the Quality of Well-Being (Mittal et al, 2006 
and Pyne et al, 1997), one used the 15D (Saarni et al, 2007), and one used the SF-
12 with utility weights derived from a convenience sample (Wells et al, 2007). As this 
gives insufficient evidence to draw conclusions about the validity and effectiveness of 
these five measures, the focus of the review became on EQ-5D and SF-6D only. A 
further three papers were therefore excluded, leaving 26 papers (see Figure 1). 
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Figure 1: Paper Identification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Included papers can be categorised into three. Those which explicitly look at the 
usefulness of utility measures in depression and anxiety (of which there are 8, see 
Table 1); those which use utility measures to consider the burden of depression and 
anxiety (of which there are 7, see Table 2) and those which use utility measures in 
clinical trials of depression and anxiety (of which there are 11, see Table 3). Further 
details of the papers can be found in Appendix 1.  
 
Table 1: Validity and responsiveness of EQ-5D or SF-6D 
Study Patient group. Country Utility measure Contribution 
Unique records 
identified through 
database searching 
(n =  479) 
Records included after 
screening of titles and 
abstracts 
(n=51) 
 
   
 
Records excluded 
after screening of 
titles and abstracts 
(n=427) 
 
   
 
Articles included 
(n=23) 
Full text articles 
excluded 
(n=29) 
 
 
Articles identified 
following-up 
references 
(n=6) 
Articles included  
(n=29) 
Articles using less 
common utility 
measures 
(n=3) 
Articles for final review  
(n=26) 
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Gunther, 08 DE. Germany EQ-5D CV, R 
Konig, 10 Anxiety disorder. Germany EQ-5D KGV, CV, R 
Lamers, 06 Mood and anxiety disorders. 
Netherlands 
EQ-5D, SF-6D KGV, R 
Mann, 09 Depression. UK EQ-5D, SF-6D KGV, CV, R 
Petrou, 09 Post-natal depression. UK EQ-5D, SF-6D KGV 
Revicki, 08 GAD. US SF-6D KGV, CV 
Sapin, 04 MDD. France EQ-5D KGV, CV, R 
Supina, 07 Population survey. Canada EQ-5D KGV 
KGV = known group validity, CV = convergent validity, R = responsiveness 
 
Table 2: Burden of depression and anxiety as measured by EQ-5D or SF-6D 
Study Patient group, country Utility measure Contribution 
Aydemir, 09 MDE patients. Turkey EQ-5D KGV, CV 
Fernandez, 10 Survey PC patients. Spain SF-6D*  KGV 
Mychaskiw, 08 GAD patients. US EQ-5D KGV, R 
Saarni, 07 Population survey. Finland EQ-5D KGV 
Sobocki, 07 Depressed patients. Sweden EQ-5D KGV, R 
Stein, 05 Anxiety disorder patients. US SF-6D*  KGV 
Zivin, 08 Veterans with depression, US SF-6D*  KGV 
*SF-6D derived from the SF-12 
 
Table 3: Trials on depression and anxiety using EQ-5D or SF-6D  
Study Patient group (n) Utility measure Contribution 
Bosmans, 08 Patients with depression in 
PC. Netherlands 
EQ-5D R 
Caruso, 10  DE in PC. Italy (FINDER) EQ-5D R 
Ergun, 08 MDD. Turkey EQ-5D CV, R 
Fernandez, 05 MDD outpatients. Europe EQ-5D R 
Reed, 09 DE in PC. Europe. 
(FINDER) 
EQ-5D KGV 
Konig, 09 Anxiety disorder in PC. 
Germany 
EQ-5D  R 
Peveler, 05 DE. UK EQ-5D R 
Pyne, 10 Depressed patients. USA SF-6D*  R 
Serfaty, 09 Geriatric depression. UK EQ-5D R 
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van Straten, 08 Selected into self-help for 
depression, anxiety and 
stress. Netherlands 
EQ-5D R 
Swan, 04 DD and moderate-severe 
episode. UK 
EQ-5D R 
*SF-6D derived from the SF-12 
 
Quality of included studies 
Quality assessment of the studies was restricted to items relating to utility measures. 
All but 3 studies (Caruso et al, 2010; Ergun et al, 2007, Reed et al, 2009) reported 
tests for statistical significance relevant to tests of validity and responsiveness. As 
can be seen in Appendix 1, many studies do no completely report details on how 
missing outcome measure  data was dealt with. 
 
 
Validity and responsiveness of the EQ-5D 
 
Known group validity of the EQ-5D 
The EQ-5D is able to identify a utility detriment for patients with depression and 
anxiety disorders. In a Finnish population survey, controlling for somatic and 
psychiatric comorbidity, depressive disorders reduced EQ-5D by -0.091, anxiety 
disorders by -0.114, GAD by -0.110, MDD by -0.058, dysthymia by -0.122, social 
phobia by -0.102 (Saarni et al, 2007). A Canadian population survey found EQ-5D 
values for those with MDE only (recurrent and current) of 0.83, those with anxiety 
only of 0.84, those with anxiety and MDE of 0.70 and those with neither of 0.92 
(Supina et al, 2007). More of the population experience both conditions (5.2%) than 
MDE alone (2.6%) emphasising the interconnectedness of these conditions. 
 
The EQ-5D also shows significant differences by severity group for MDD patients 
(Sapin et al, 2004 and Sobocki et al, 2007), those with general mood and anxiety 
disorders (Lamers et al, 2006), and those with GAD (Mychaskiw at al, 2008). For 
example, Sobocki et al (2007) find an average EQ-5D score of 0.6 for mild 
depression (95% CI 0.54-0.65), 0.46 (95% CI 0.30-0.48) for moderate, and 0.27 
(95% CI 0.21–0.34) for severe. Between group differences are not always significant 
(for example, the data above does not find a significant difference between average 
values for moderate and severe depression), often due to the high standard deviation 
of the EQ-5D. Aydemir et al (2009) is an exception as they do not find that the EQ-5D 
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significantly identifies MDD single episode versus recurrent episodes for patients in 
Turkey. The mental health summary component of the SF-36 also does not identify 
this group difference. Interestingly, they do find a significant difference between 
single and recurrent MDD episode in the physical functioning score of the SF-36, the 
physical health summary score and general health perception.  
 
For patients with anxiety disorder, Konig et al (2010) find that almost all EQ-5D 
dimensions response levels (but particularly anxiety and depression) are associated 
with significant differences in scores of WHOQOL domains and measures of 
psychopathology, such as the BAI score.  
 
To further understand the ability of the EQ-5D to identify patients with depression and 
anxiety it is useful to consider where health loss is identified across EQ-5D domains. 
For depressed patients this is in the domains of depression and anxiety, pain and 
discomfort, usual activities, and to a lesser extent mobility and self-care (see Table 
4). The picture is remarkably similar across different studies conducted in different 
countries, supporting the reliability of the EQ-5D. Some differences arise due to 
different exclusion criteria across studies, particularly where comorbid physical 
conditions are excluded (e.g. Aydemir et al, 2010), which leads to less health loss on 
the pain dimension. Anxiety and affective disorder give a similar pattern of domain 
problems, but with less reporting of problems in the anxiety and depression domain. 
 
Table 4: Health loss by dimension on the EQ-5D. % reporting moderate or 
extreme problems   
Patient group Mobility  Self-care Usual 
Activities 
Pain / 
Discomfort 
Anxiety / 
Depression 
MDE (DSM-IV), 
excluding comorbid 
condition  
(Aydemir, 10) 
28.4  16.3 64.8 43.2 98.7 
MDD (SCID)  
(Mann, 09) 
27 16.2 75.7 64.2 94.5 
MDD (DSM-IV) 
(Sapin, 04) 
26.5 16.2 75.2 64.1 99.1 
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DE (ICD-10) 
(Gunther, 08) 
28.8 26.9 66.4 66.0 78.8 
Anxiety disorder 
(Konig, 10) 
23 3.9 40.8 71.5 77.4 
 
 
Comorbidity is very prevalent in patients with common mental health problems. For 
example, in Swedish patients diagnosed with depression in primary care 59% have 
one comorbidity (56% physical and 9% psychiatric) (Sobocki, 2007). A separation of 
mental and physical health does not therefore fit well for this patient group as the 
health impact of depression and anxiety is connected to both mental and physical 
health. 
 
What is not clear, however, is whether the EQ-5D is picking up the impact of 
depression and anxiety on health domains beyond the anxiety and depression 
domain or whether the impact arises from other somatic or psychological 
comorbidities.  
 
Convergent validity of the EQ-5D 
The EQ-5D shows good correlation to clinician-rated measures of depression 
severity (-0.539 to -0.77) for depressed patients. Correlations to functioning (0.492), 
patient rated severity (-0.451 to -0.638) and patient rated quality of life (0.43 to 0.63) 
are also moderately good (see Table 5). 
 
For patients with anxiety, Konig et al (2010) find a stronger correlation between EQ-
5D and the physical health component of the WHOQOL-BREF than with the mental 
health component and moderately good correlations to depression measures (0.54 
for the BDI-II). The Beck Anxiety Inventory correlates at 0.53, however, other self-
complete measures of anxiety show correlations of 0.4 and below. This suggests a 
general pattern whereby the EQ-5D is best at identifying mental health conditions 
which also impact upon physical health, then those which impact upon depression, 
but less effective at picking up anxiety. 
 
Table 5: Correlations of EQ-5D and clinical/quality of life measures 
Scale Type Correlation Patient group 
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HAM-D. Depression severity CS -0.77 MDD (Aydemir, 09) 
BRAMES. Depression severity CS -0.576 DE (Gunther, 08) 
CGI. Severity of illness CS -0.539  
GAF. Occupational functioning  CF 0.492  
EQ-VAS  PQoL 0.440  
PHQ-9. Depression symptoms PS -0.451 baseline 
-0.638 follow up 
Patients with depression 
(Mann, 09) 
SF36 MHC PQoL O.49 baseline 
0.56 day 28 
0.63 day 56 
MDD (Sapin, 04) 
QLDS PQoL -0.43 baseline 
-0.68 day 56 
 
SF36 MHC PQoL O.49 baseline 
0.63 day 56 
 
WHOQOL physical health, mental 
health 
PQoL 0.7, 0.5 Anxiety disorder (Konig, 
10) 
Anxiety scales: BSQ, ACQ, MIA, 
MIB, BAI 
PS -0.40, -0.32, -0.35, 
-0.36, -0.53 
 
Depression scale. BDI-II PS -0.54  
CS = Clinician rated symptoms, CF = Clinician rated functioning, PF = patient completed 
functioning, PS = Patient completed symptoms, PQoL = patient assessed quality of life 
  
Interestingly, correlations with patient quality of life (Sapin et al, 2004) and patient 
completed symptom scales (Mann et al, 2009) are stronger at endpoints than 
baseline. This suggests a stronger correlation between EQ-5D and patient reported 
depression outcome measures for milder states. 
 
Regression analysis shows EQ-5D to be related to expected variables for depressed 
patients (Caruso et al, 2010, Reed et al, 2009, Soboki et al, 20002). For example, it 
has a significant negative relationship between the number of previous depressive 
episodes, the duration of the current episode, and somatic symptoms (Reed et al, 
2009). Soboki et al (2002) find that clinical severity variables explain 23% of the 
variation in EQ-5D for depressed patients, with demographic variables not being 
significant. Models including patient rated quality of life find 40% of the variation in 
EQ-5D explained (Sapin et al, 2004). 
 
Responsiveness of the EQ-5D 
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In general the EQ-5D is very responsive to improvement in both depressed (Caruso 
et al, 2010, Ergun et al, 2007, Fernandez et al, 2005, Sapin et al, 2004; Sobocki et al, 
2007; Swan et al, 2004; Reed et al, 2009) and anxious patients (Konig et al, 2010) 
and performs as well as symptom based, functioning and quality of life measures. In 
some studies, despite substantial change, improvement is not significant due to the 
high standard deviation (Peveler et al, 2005). Studies also find substantial differences 
between patients identified as in remission versus those who are not (Mann et al, 
2009, Sapin et al, 2004) 
 
For depressed patients, effect size, and SRM are broadly in line with other measures, 
but lower in some studies due to higher standard deviation of EQ-5D relative to other 
measures. Van Straten (2008) find a Cohen’s D of 0.44 for self-selected members of 
the public who complete a self-help course for depression, anxiety and stress. This 
compares with a Cohens D of 0.67 for the CES-D and 0.56 for the MDI (both patient 
completed symptom measures of depression), 0.51 for the SCL-A (a clinician rated 
symptom list for anxiety) and 0.48 for the HADS (clinician rated symptom list for 
depression). Lamers et al (2006) follow patients with a diagnosis of mood and anxiety 
disorders (major depression, dysthymic, social phobia, generalised anxiety) over an 
18 month period. Despite a greater increase in the EQ-5D than the SF-6D they find 
an SRM about half that of the SF-6D. 
 
Konig et al (2010) find that for anxiety patients the t statistic, ES and SRM of the EQ-
5D are higher than for other measures (WHOQoL, BSQ, ACQ) for patients who 
become more anxious but for those who become less anxious the relative 
performance of the EQ-5D is mixed, being lower than BSQ and ACQ but higher than 
the WHOQoL. Konig et al (2009) find the EQ-5D to be in line with other anxiety 
measures (BAI and BDI-II) in showing no difference between and intervention and 
control group. Similarly, Bosmans et al (2008) find no significant difference between 
intervention and control group for depressed patients in primary care, in line with the 
MADRS depression scale. 
 
Increases in the EQ-5D are positively related to disease severity for depression 
(Gunther et al, 2008, Lamers et al, 2006; Sobocki et al, 2007) which is indicative of a 
ceiling effect.  
 
The findings of Serfaty et al (2009) are an exception to the general picture of 
responsiveness of the EQ-5D. Here the EQ-5D is less responsiveness than the BDI-
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II. The patient group in this study has a mean age of 74.1, suggesting the EQ-5D 
may lack responsiveness for older patients. 
 
Table 6: Responsiveness of the EQ-5D 
Patient group Responsiveness evidence Significant 
difference 
Depressed 
patients 
(Bosmans, 08) 
No significant difference between intervention and 
control group. In line with MADRS measure.  
No 
MDD (Ergun 07) Mean score increased from 0.44 to 0.91 at 6 weeks. 
 
NA 
Depressed 
patients (Caruso, 
10)  
Improvement of 0.26 at 3 months, 0.33 at 6 months.  NA 
Severe MDD 
(Fernandez, 05) 
Improvement at 8 weeks on Escitalopram and 
Venlafaxine 
 
Yes 
DE (Gunther, 08) EQ-5D showed deterioration for those in worst 
health according to patient perceptions and 
BRAMES score and improvement for those in better 
health, but the later less so than other measures.  
T statistic, ES and SRM find greater 
responsiveness of EQ-5D (UK and German index) 
to deteriorating health than clinical measures 
(almost twice as large), but less responsive to 
health improvement: half the ES of CGI.  
 
Yes 
Anxiety disorder 
(Konig, 09) 
No difference between intervention and control 
group. BAI and BDI also showed no differences. 
 
No 
Anxiety disorder 
(Konig, 10) 
Effect size for more anxiety (a BAI increase of more 
than 0.5 of SD) -0.99, which was twice as big as 
other measures (WHOQoL, BSQ, ACQ).  
Effect size for less anxiety, 0.39. 
SRM -0.54 for more anxiety, again higher than other 
measures.  
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SRM 0.46 for less anxiety (BSQ -0.72, WHOQoL 
0.35). 
 
Mood disorder 
(Lamers, 06) 
Improvement of 0.167 at 1.5 years. 
Mean improvement in EQ-5D increased with 
severity. 
SRM was 0.466 (about half that for SF-6D) 
 
Yes 
Depressed 
patients  
(Mann, 09) 
Mean score increased by 0.147 at 3 months. 
Median score increased by 0.069. 
Those classed as in remission (62% of sample) 
showed an increased in EQ-5D of 0.243. 
 
Yes 
Depressed 
patients 
(Mychaskiw, 08) 
Those in functional remission 0.26 higher than 
those not in remission. Those in symptomatic 
remission 0.24 or 0.26 higher, depending on HAMA 
cut off. 
 
 
Yes 
Depressed 
patients  
(Peveler, 05) 
Improvement of 0.22 at 12 months. No 
Depressed 
patients  
(Reed, 09)  
Improvement at 3 months NA 
MDD (Sapin, 04) Improvement of 0.35 at 4 weeks and 0.45 at 8 
weeks. Only 9.3% extreme problem with anxiety / 
depression after 77.9% at baseline. 
Able to distinguish responder-remitters, responder 
non-remitters and non-responders based on 
MADRS score. 
 
 
Depressed 
patients  
(Serfaty, 09) 
Mixed evidence on responsiveness. BDI-II found 
clearer improvement from baseline to 4 and 10 
months and found CBT intervention superior to 
TAU. EQ-5D did not show superiority of CBT over 
No 
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TAU. 
 
Depressed 
patients  
(Sobocki, 2007) 
EQ-5D increased by 0.23 at 6 months (or last 
followup). Increase in EQ-5D positively related to 
disease severity (CGI-S). 
 
Yes 
Public recruited 
for self-help  
(van Straten, 08) 
Improvement pre/post intervention. 
Effect sizes: Cohens D (course completers) 
CES-D 0.5 (0.67); MID 0.33, (0.56); SCL-A 0.42, 
(0.51) 
HADS 0.33, (0.48); EQ-5D 0.31, (0.44) 
MBI work stress not significant. 
 
Yes 
Depressed 
patients previous 
inadequate 
response  
(Swan, 04) 
Of those that attended follow up, improvement 
found at week 12 and 26. In line with changes in 
GSI and BDI. 
Yes 
 
 
Validity and responsiveness of the SF-6D 
 
Known group differences of the SF-6D 
The SF-6D shows significant differences between disease severity groups (SCL 
subgroups) for mood disorder patients (Lamers et al, 2006) and for subgroups based 
on HAM-A scores for GAD patients (Revicki et al, 2008).  
 
The utility detriment for depression and anxiety has been identified using the SF-6D 
(estimated from the SF-12) in a number of population surveys. Analysis of US survey 
data shows that the SF-6D identifies significantly lower utility for veterans with 
depression than without depression (0.57 versus 0.63) (Zivin et al, 2008). US 
outpatient data shows a drop in the SF-6D of -0.122 for anxiety disorder and -0.087 
for major depression (Stein et al, 2005). Fernandez et al (2010) conduct quantile 
regressions on SF-6D values from a sample of patients from Spanish primary care. 
At the median they find a drop in utility of -0.20 for mood disorder and -0.04 for 
anxiety disorder (Fernandez et al, 2010).  
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In a sample of 114 patients with depression in the UK health loss is identified by the 
SF-6D in the domains of mental health (100%), vitality (98.8%), role limitation 
(98.8%), social functioning (89.1%), pain (78.7%) and physical functioning (22.1%) 
(Mann et al, 2009). As with the EQ-5D the SF-6D is picking up either the impact upon 
health of comorbidities, or a more holistic impact of depression and anxiety. 
 
Convergent validity of the SF-6D 
One study looked at the convergent validity of SF-6D for patients with GAD (Revicki 
et al, 2008). The SF-6D correlates -0.38 with GAD-Q-IV (a diagnostic measure of 
GAD), -0.52 with HAM-A (a severity score for GAD) and -0.64 with the PHQ-9 (a 
patient completed depression scale). Symptom measures explain 46% of the 
variance of SF-6D, suggesting a close relationship. The stronger correlation with the 
depression measure than the anxiety measures suggests that either public 
preferences give greater weight to changes in depression severity than anxiety or 
that the SF-6D measure is not as sensitive to changes in anxiety as it is to changes 
in depression. This pattern reflects that found for the EQ-5D. 
 
Responsiveness of the SF-6D 
Two studies compare the responsiveness of the SF-6D versus the EQ-5D, in MDD 
(Mann et al, 2009) and general mood disorder patients (Lamers et al, 2006). 
Although the SF-6D shows significant change over time, and distinguishes those 
patients in remission, the absolute improvement in both studies is higher for the EQ-
5D. Mann et al (2009) find that mean improvement is higher for the SF-6D in the low 
severity group but lower than the EQ-5D in the two high severity groups. However, 
due to its lower SD the SRM is at least twice as high as that for the EQ-5D (0.833 for 
SF-6D versus 0.466 for EQ-5D at 1.5 years follow up). 
 
SF-6D versus EQ-5D 
Both the EQ-5D and the SF-6D perform reasonably well in terms of convergent 
validity with other measures, known group validity and responsiveness. However, 
evidence suggests they are not substitutes. 
 
Lamers’ study in the Netherlands includes both the EQ-5D and the SF-6D (Lamers et 
al, 2006). At baseline, more respondents report having no limitations when using the 
EQ-5D than when using the SF-6D and less report problems at the severe end of the 
scale. For example, 78% report no mobility problems and 93.5% report no problems 
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with self-care according to EQ-5D yet only 18% report no limitations in physical 
functioning in SF-6D. Fewer respondents report the most severe level of mental 
health problems with the EQ-5D than the SF-6D: 65% report 4 or 5 out 5 for mental 
health responses on the SF-6D yet only 33% report 3 out of 3 for the EQ-5D. 
 
This pattern is replicated in UK patients with depression (Mann et al, 2009). 73% and 
83.8% report no mobility or self-care problems on the EQ-5D respectively, yet only 
27.9% report no physical problems on the SF-6D. 86.6% of patients report feeling 
tense/downhearted or low most or all of the time using the SF-6D but only 29.4% 
report extreme problems with anxiety and depression on the EQ-5D. 57.1% report 
the most severe level on vitality for which there is no comparable measure in the EQ-
5D. 
 
The greater mental health loss reported on the SF-6D may be due to the fact that SF-
36 and SF-12 asks questions about feelings whereas the EQ-5D domain ‘depression 
or anxiety’ sounds more clinical (Mann et al, 2009: p574). Alternatively, this may be a 
consequence of using 5 rather than 3 levels.  
 
Despite the fact that SF-6D appears to identify more health loss, in the study by 
Mann et al (2009) the EQ-5D shows greater responsiveness with larger health gains 
for all patients at follow up and for those in remission. This arises in part through the 
lower average score on the EQ-5D for severely depressed patients at baseline 
(0.337 versus 0.544 for the SF-6D). Lamers et al (2006) also find mean improvement 
in EQ-5D to be higher than the SF-6D for the two most severe subgroups, although 
lower than the SF-6D for low severity groups.  
 
The SF-6D generally outperforms the EQ-5D in terms of effect size and SRM in part 
as a consequence of the lower standard deviation, and the more normal distribution 
of the SF-6D. Consistently, EQ-5D has higher (by 2-3 times) standard deviation. 
 
The study by Petrou et al (2009) which looks at levels of health for women six 
months postpartum has been included in this review because it offers another 
comparison the performance of the EQ-5D and the SF-6D in identifying levels of 
health these women, some of whom may have post-natal depression. They find the 
SF-6D to have better discriminatory ability when women are compared across self-
reported health status groups, and by two alternative cut off scores on the Edinburgh 
Post Natal Depression Scale; the SF-6D generating higher area under the ROC 
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scores. The mean EQ-5D is significantly higher than the SF-6D and the minimum 
EQ-5D in the sample was 0.077, much lower than that of the SF-6D at 0.374. 177 
women (35.9%) had full health according to the EQ-5D yet had an SF-6D score of 
below 1 (29.2% and 34.1% identifying problems with mental health and vitality, 
respectively). Whereas only one women had an SF-6D of 1 yet identified moderate 
pain/discomfort on EQ-5D. The authors suggest four possible reasons for the greater 
sensitivity of the SF-6D to maternal health. First, the SF-6D taps into broader aspects 
of health and quality of life. Secondly, the SF-6D has a greater number of response 
items. Thirdly, the wording on SF-6D includes positive and negative items. And lastly, 
the SF-6D refers to a longer time frame (past 4 weeks) versus the EQ-5D which 
refers to today. 
 
The SF-6D therefore appears better at picking up mild mental health problems, 
whereas EQ-5D gives greater weight to those with severe mental health problems. 
This pattern is not unique to mental health and has been identified in a number of 
conditions (Brazier et al, 2004). This difference arises due to differences in 
classification system and valuation technique; TTO for the EQ-5D and SG for the SF-
6D. Tsuchiya et al (2006) find a cross over relationship where the SG SF-6D protocol 
generates values which are higher than the EQ-5D TTO protocol, yet for milder 
states TTO values are higher than SG values. This cross over point has been 
estimated to be 0.754 on the EQ-5D (Barton et al, 2008).  
 
The worst state which can be described by the descriptive system is worst for EQ-5D 
than SF-6D, as the SF-6D does not cover very severe states (Brazier et al 2004). 
This may in part explain why the lowest value on the SF-6D is +0.291 whereas for 
the EQ-5D the lowest value is -0.59.  
 
If the SF-6D is an accurate representation of preferences then the EQ-5D risks 
missing health change at the top end and overstating the value of change at the 
severe end. Alternatively, if EQ-5D is better reflection of preferences the SF-6D 
identifies change at the top end that is not meaningful for resource allocation 
decisions and understates change at the severe end.  
 
Further evidence on whether EQ-5D or SF-6D most closely reflects the utility loss 
from depression and anxiety may be sought by making comparisons with direct utility 
valuations of depression and anxiety. These comparisons may come either from 
utility values derived directly from patients with depression or anxiety, from patients 
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who have previously been in those health states, or from valuations from the general 
public who are given more detailed scenarios describing these health states. 
 
The range of severity and episodic nature of common mental health problems 
presents a challenge for valuation. Ideally, we require values for different levels of 
severity of depression and anxiety in addition to states of remission. Combining utility 
scores for patients with general depressive or anxiety disorder will disguise much of 
these differences. Furthermore, severity is likely to be related to study involvement 
and completion, suggesting values may be an overestimate of average patients.  
 
Some studies which have conducted trade off exercises with patients with depression 
or anxiety suffer from failure of participants to make any sacrifice of length of length 
in TTO exercises or risk of death in SG exercises. Konig et al (2009) conducted TTO 
exercises with patients with affective disorder in psychiatric hospital in Germany. 
29.4% of patients did not trade in the TTO exercise and the likelihood of being a non-
trader was related to quality of life. Failure to trade is particularly problematic for 
postal surveys with this patient group (see Wells et al (2007) and Donald-Sherbourne 
et al (2001)). As these non-traders effectively rate their health state as full health, this 
leads to higher average utility value, suggesting lack of confidence in findings of 
postal surveys for this patient group.  
 
Table 7 gives a summary of direct health state utility values for patients experiencing 
depression and anxiety (excluding those based on postal surveys (Wells et al, 1999, 
Donald-Sherborne et al, 2001 and Isacson et al, 2005). It is difficult to compare those 
from Bennett et al (39) since they incorporate a unique McSad descriptive system, 
the other studies show values ranging from 0.60 for moderate-severe depression and 
0.74 for mild or general depressive disorder.  
 
Direct valuations with patients with depression and anxiety are only slightly correlated 
with generic utility scores. Konig et al (2009) find that TTO scores correlate 0.31 with 
EQ-5D UK index and 0.24 with the EQ-5D German index in patients with anxiety 
disorder. Revicki and Wood (1998) find SG responses from 70 patients diagnosed 
with depressive disorder correlate at 0.29 with EQ-5D. This relatively low correlation 
may arise if public valuation studies give different weights to health attributes 
compared with depressed or anxious patients.  
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Lenert et al (2000) compare SG values for self-rated health of 71 patients with 
depressive symptoms with utility values from the SF-12 for the same state and do not 
find a significant difference. Depressed patients with near normal health tended to 
rate their current health as less preferable than the matched state, those with poorer 
health rated current health as more preferable than the matched state. This might 
suggest that utility scores overstate the health loss from severe depression states yet 
understate that from mild depression. The SF-12 utility score used here is not the SF-
6D, so a direct comparison is not possible, but this does indicate that public 
preferences might undervalue mild mental health loss and over-value severe mental 
health loss relative to patient valuations, which would favour use of the SF-6D over 
the EQ-5D. 
 
Table 7: Direct valuation on own current health 
Study Condition Method Value 
Bennett 00, 
Canada 
Depressed patients in primary care with at 
least one unipolar episode of major depression 
SG 
McSad 
0.79 
Fryback 93, 
USA 
Major depression TTO 0.70 
Pyne 09, USA Mild to moderate depression (PHQ9 of 5-14)  SG 0.74 
 Moderate to severe depression  SG 0.60 
Revicki & Wood 
98, USA 
Depressive disorder  SG 0.74 
Konig 09, 
Germany 
Patients in psychiatric hospital with affective 
disorder  
TTO 0.66 
 
 
Earlier studies on valuations of hypothetical states for depression have found much 
lower values, for example, Sackett and Torrance (1978) find a value of 0.44 using 
TTO (and a duration of 3 months) on a population survey in Canada. Table 8 shows 
utility values drawn from hypothetical valuations from: members of the general public; 
those with a recent history of depression; and those currently experiencing a 
depressive episode.  
 
Values for severe depression range from 0.04 to 0.68. The values from Bennett et al 
(2000), which uses the McSad descriptive system, are far lower than any other value. 
This makes direct comparisons problematic, however, they do point to a substantial 
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health loss from severe depression states that may not be being reflected in other 
utility scores possibly because severe states are not adequately described. 
 
Currently depressed patients rate depression as lower than either general public or 
previously depressed patients (Pyne et al, 2009; Schaffer et al, 2002) and severely 
depressed patients rate depression states lower than mildly depressed patients 
(Pyne et al, 2009). The proportionate differences between population and patients 
valuations increases with hypothetical depression severity. However, those patients 
who have a history of depression, but are not currently depressed, rate depression 
similarly to the general public (Pyne et al, 2009; Schaffer et al, 2002)  
 
Table 8: SG valuations of hypothetical scenarios 
Study Who values Mild  Moderate Severe 
Bennett 00  
Canada 
105 depressed primary care patients in 
remission  
0.59 0.32 0.09 
 As above (life time)   0.04 
Pyne  09 Population  0.87 0.77 0.63 
USA History of depression (PHQ-9 < 5)  0.89 0.80 0.68 
 Current Mild-moderate depression 
(PHQ-9 5 to 14)  
0.87 0.74 0.63 
 Current Severe depression (PHQ-
9>=15)  
0.79 0.69 0.58 
Revicki & 
Wood, 98 
USA/Canada 
Patients with depressive disorder    0.30 
Schaffer 02 
Canada 
Currently depressed patients 
(HRSD>=16)  
0.59 0.51 0.31 
 Patients with DD not currently 
depressed (HRSD<16)   
0.79 0.67 0.47 
 Population  0.80 0.69 0.46 
 
 
The lower valuations of currently depressed patients have been explained by 
negative cognitive distortions (Pyne et al, 2009) including all or nothing thinking and 
over-generalising negative events. However, when patients assessed their own 
health imagining not having depressive symptoms no differences were found (Pyne 
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et al, 2009). Where some depressed patients are suicidal this might lead to lower 
valuations because they are happy to risk death in SG and shorten their life in TTO. 
However, Schaffer et al (2002) find no difference in utility valuations between 
depressed patients with suicidal thoughts and those without. 
 
Differences may arise through changes in preferences between depressive episode 
and remission. Alternatively, they may arise from a different understanding or 
interpretation of the condition. Those patients who are currently in remission may 
have more limited experience of severe states of depression compared with those 
currently in a depressive episode. 
 
One of the difficulties of valuing depressive states is that, for most SG questions 
respondents are required to imagine a permanent state, yet, depression is generally 
a time limited state. Those in remission may be more aware of the episodic nature of 
the condition than those currently experiencing the state. Furthermore, the cognitive 
demands of TTO and SG exercises may be problematic for patients currently 
experiencing depression or anxiety. 
 
Looking at the evidence on direct utility valuations for depression and anxiety 
presents a mixed picture. Evidence from patients valuing their own health using 
direct TTO or SG questions supports higher utility values for severe and moderate 
depression found by the SF-6D. However, TTO/SG trade-off exercises are subject to 
high numbers of currently depressed/anxious patients not being willing to trade. 
 
Evidence from patients valuing scenarios describing depressive states finds that 
patients currently experiencing severe depression valuing severe depression as 
lower (0.3, 0.31, 0.58) and more in line with lower values found from the EQ-5D. Yet 
those who are no longer currently in a depressive state value severe depression 
higher and are more supportive of the SF-6D values. 
 
 
Summary 
The SF-6D and EQ-5D demonstrate good construct validity and responsiveness for 
patients with depression. They can both distinguish between groups that are known 
to vary according to severity of depression, and across differences in quality of life of 
depressed patients. Both measures respond to clinical and quality of life 
improvement and deterioration. Indeed, in many cases they are more responsive 
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than depression specific measures. This is likely to be due to integrated nature of 
mental and physical health problems and potential simultaneous improvement in co-
morbid conditions. More evidence is required on the validity and responsiveness of 
generic measures for older people with depression, since this group may be an 
exception. 
 
The performance of EQ-5D and SF-6D for patients with anxiety is a little more mixed. 
The  EQ-5D and SF-6D are more highly correlated with depression scales in patients 
with anxiety than they are clinical anxiety scales. The ability of utility measures to 
distinguish between sub-groups of patients with anxiety may be driven by aspects of 
depression within anxiety disorder and the presence of co-morbid depression. More 
work is required to test whether EQ-5D and SF-6D are sensitive to changes in 
anxiety alone. 
 
For both anxiety and depression the EQ-5D is better at identifying those who 
increase in severity compared with those who show improvement. Those patients 
moving into a level 3 on any dimension on the EQ-5D incur an additional detriment 
(0.269) according the UK tariff (the N3 term). For example, moving from health state 
11222 to health state 11223 brings a change in utility score from 0.689 to 0.255. 
Deterioration of already depression or anxious patients may result in patients moving 
to level 3 for depression and anxiety. 
 
The relationship between the EQ-5D and the SF-6D reflects that found for other 
conditions. The EQ-5D shows a lower level of utility at the most severe end for 
depression, the SF-6D shows equal or greater detriment at the milder end. The SF-
6D identifies utility loss in patients that report full health on the EQ-5D, however, 
patient averages for mild depression and anxiety are still able to show lower than 
normal population utility using the EQ-5D. 
 
Turning to direct utility estimation for depression and anxiety states does not help 
distinguish between validity of EQ-5D over SF-6D. Whilst severely depressed 
patients rating scenarios of severe depression give values closer to those found by 
the EQ-5D, depressed patients rating their own health and ex-depressed patients 
rating severe depression give values that are significantly higher. More research is 
needed to understand the source of these different values. Recent developments in 
bringing five dimensions to the EQ-5D (Pickard et al, 2008) may help illuminate the 
cause of difference in utility values between EQ-5D and SF-6D. 
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Table A.2: Validity and responsiveness assessment methods used in studies, trials, health burden, and validity/responsiveness  
 
Study  
Author, Year 
Location 
Sample  Descriptive 
system (i.e. 
EQ-5D, SF-
36) 
Utility values at 
baseline 
 
Validity results Responsiveness results Authors' 
conclusions & 
comments 
Aydemir et al, 2009  Turkey  See Ergun et al for related trial data 
74 patients, 18-65 years, diagnosed major depressive episode according to DSM-IV criteria. Exclusion: other psychiatric disorder, comorbid condition. Mean age 39.6 years, 63.5% female. 32.4% recurrent depression 
HAM-D, SF-36,  EQ-5D UK   EQ-VAS 
Highest mean SF-36 score in physical function (79.2) and lowest in vitality (23.9).  EQ-5D levels (no difficulties/moderate/extreme) Mobility (71.6/27.0/1.4) Self-care (83.8/14.9/1.4) Usual care (35.1/40.5/24.3) Pain/discomfort (56.8/37.8/5.4) Anxiety/depression (1.3/36.5/62.2) EQ-5D index 0.4 (SD 0.3) EQ-VAS 38.2 (SD 22.3) 
Single: EQ-5D 0.45 (SD 0.29) Recurrent: EQ-5D 0.41 (SD 0.31) Not sig. different  The physical component summary of the SF-36 found patients with recurrent depression to be in significantly poorer health.  The mental health summary component summary of the SF-36 showed no significant differences between single and recurrent depression.  EQ-5D correlated at -0.77 with HAM-D.  
  
 39 
Bosmans et al 2008  The Netherlands 
Patients with minor or mild-major depression in primary care. Exclusions: Currently receiving antidepressants (AD) or psychological therapy  RCT: n=44 Usual care no AD. Mean age 48, 73% female  n=45 Usual care plus AD, mean age 46, 76% female 
MADRS EQ-5D UK EQ-5D No AD 0.64 (SD 0.26) AD 0.66 (0.23)  Mean difference in QALYs gained between the two groups -0.00045 (95% CI -0.093; 0.084)  Difference in improvement in MADRS score -0.81 (95% CI -5.6; 4.0) 
 
Caruso et al, 2010  Italian data from FINDER, 6 month observation study in 12 European countries 
N=513 patients in primary care with clinically diagnosed episode of depression requiring pharmacological treatment.   Mean age 49.2, 72.9% female. 
HADS-D HADS-A SSI-28 VAS pain  SF-36 EQ-5D  
 Regression analysis explored predictors of EQ-5D (n=328).  EQ-5D at 6 months significantly related to: - Switching antidepressants  - EQ-5D at baseline,  - SSI-somatic at baseline -  no of episodes of depression,  
EQ-5D Baseline: 0.40 (SD 0.01) 3 month: 0.66 (SD 0.26) 6 month 0.73 (SD 0.23)   EQ-VAS Baseline: 45.7 (SD 19.6) 3 month: 61.3 (SD 17.9) 6 month: 69.3 (SD 17.0)   
 
 40 
Data recorded at baseline, 3 & 6 months. - chromic medical condition  - VAS pain at baseline - number of dependents  - HADS-A at baseline  VAS scores at 6 months significantly related to - EQ-VAS at baseline, - any psychiatric illness in last 2 years - switching antidepressants - occupational status - age  - VAS pain at baseline Ergun  Turkey  Abstract only published  
74 patients with major depressive disorder in RCT. EQ-5D UK HAM-D Mean at baseline EQ-5D 0.44 (As above) HAM-D correlates 0.77 with EQ-5D. EQ-5D increase from mean 0.44 at baseline to 0.91 at 6 weeks follow up.   
Possible typo in SD 
Fernandez et al, 2005  8 European countries  RCT of Escitalopram vs venlafaxine 
293 outpatients (aged 18-85) fulfilling DSM-IV criteria for severe MDD, without suicidal tendencies. Exclusion: history mania, bipolar, 
EQ-5D UK QLDS MADRAS At baseline >2/3rds had some or severe problems in the dimensions for pain, anxiety/depression and usual activities. 
 EQ-5D  Baseline to Week 8 Escitalopram arm: 0.52 to 0.78 (p<0.001) Venlafaxine arm: 0.54 to 0.77 (p<0.001) 
 
 41 
XR in MDD schizophrenia or psychotic disorder, evidence of OCD, eating disorder, mental retardation, pervasive development disorder.  Escitalopram (n=126) Mean age 48.4, 75.4% female  Venlafaxine (n=125) Mean age 46.5, 71.2% female Fernandez, 2010  Spain    
Representative sample of 3815 primary care patients 
SF-6D from SF-12 Utility loss, adjusting for socio-demographic characteristics and morbidity  Regression model with inference at the median 12-month mood disorder -0.20 (-0.21 to -0.18) 12-month anxiety 
Median SF-6D score Any mood disorder: 0.547 (n=476) MDD: 0.527 (n=332) Dysthymia: 0.603 (n=115) Any anxiety disorder: 0.660 (n=659) Panic disorder: 0.606 (n=253) GAD: 0.681 (n=129) Social phobia: 0.599 (n=64) Specific phobia: 0.698 (n=232) Any substance misuse: 0.723 (n=122) ns 
  
 42 
disorder -0.04 (-0.06 to -0.03)  Quantile regression shows impact of mood disorder is greater at higher levels of utility. 
Alcohol misuse: 0.737 (n=81) ns 
Garcia-Cebrian et al, 2008  FINDER  European 
Patients (>= 18) with clinical depression enrolled prior to commencing antidepressant treatment, presenting to primary care or specialists.   Of 3468 at baseline, 343 had no follow up data, 271 data at 3 months only, 2854 had 3 & 6 months.   Mean age 46.8, 68.2% female  
EQ-5D EQ-VAS SF-36  HADS-D HADS-A SSI-28 VAS-pain 
Baseline scores: 51.5% experienced anxiety disorder or panic disorder in last 2 years. 42.5% had at least one co-morbid physical condition.  (n=3432) % with any problems Anxiety/ Depression: 96.6  Pain / Discomfort: 73.3 (of which 12.1% extreme)  Usual activities: 72.5 Mobility: 33.8 Self-care: 18.3  Pain 49% headache 46% soreness in muscles 
Baseline scores: HADS-D score increased with increasing pain severity No pain 11.4 (SD 4.6) Moderate 12.3 (SD 4.3) Extreme 14.4 (SD 4.2) 
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45.8% lower back 44.9% back pain 43.5% pain in joints 30.1% pain abdomen 26.3% pain chest   EQ-5D 0.44 (0.31) European population 0.85 (0.23)  EQ-VAS 44.8 (20.4) European 77 (20) Gunther et al 2008  Germany 
Patients with a depressive episode according to the ICD-10 Classification (F32.1, F32.2, F33.1, F33.2), recruited consecutively from 3 departments of psychiatry in Germany.   Patients with psychotic or manic symptoms were excluded  
EQ-5D UK and German (based on TTO)  EQ-VAS WHOQoL-BREF CGI-S, GAF BRAMES  
At baseline patients mainly report problems in: Depression and anxiety (78.8%), Usual activities (66.4%), Pain (66.0%), Mobility (28.8%) and Self care (26.9%)  Improvement found in Usual activities and Anxiety/depression.  
Correlation (Spearman rank due to non-normal distribution of EQ-5D) of EQ-5D index and VAS significant with all other measures.   VAS strongest correlation with WHO-BREF (0.642)  EQ-5D correlations BRAMES -0.576 WHO-BREF 0.545 CGI -0.539 GAF 0.492 EQ-VAS 0.440 EQ-5D German 0.945  
Disaggregating into those who think health (at assessment 18 months after baseline) is worst (16), same (39) or better (49), than at baseline.   Also disaggregated into 3 groups based on BRAMES score.  For those with perceived worst health EQ-VAS shows slight improvement in mean scores. The EQ-5D indexes both show deterioration for those in worst health (-0.290 for UK index) larger than the improvement for those in better health (0.155). Other measures show a greater change for those with better health. When patients were 
N3 term 0.269 in UK and 0.323 in Germany, hence moving away from extreme problems represents a large change in score.   Concern regarding the regression estimating meaningful difference.  Missing values on the assessments (<1.3%) were replaced by baseline or assessment values. 
 44 
disaggregated into 3 groups based on BRAMES score this gives similar results.   For t statistic, ES & SRM. EQ-5D (UK and German) t stat, ES and SRM find greater responsiveness to deteriorating health (almost twice as large as clinical measures). Although sig. differences for better health, clinical measures show greater responsiveness.  ES for health improvement: CGI most responsive (-0.98 patient-based anchor, -1.35 clinician based anchor), VAS (0.84, 1.19), EQ-5D UK (0.55, 0.65), EQ-5D German (0.41, 0.45).   Regression analysis showed sig impact of baseline score (not of age or time since diagnosis), such that the smaller the baseline score the larger the difference between assessments. For EQ-5D the coefficient for EQ-5D UK on self-perceived ‘better’ was 0.104 and clinically judged better was 0.167 (for the German index 0.059 NS and 0.106) For EQ-5D the coefficient for EQ-
 45 
5D UK on self-perceived ‘worst’ was -0.470 and clinically judged worse was -0.223 (German -0.397 and -0.139 NS, respectively) Kessing et al, 2006 Patients with depressive disorder identified from the Danish Psychiatric Central Research Register 55.3% female, Mean age 43.8 Number of admissions 2.39. 
EQ-5D dimensions only  EQ-VAS WHO (Five) well-being index a subscale of PGWB)  BDI-21 BDI-Anxiety BDI-Mania 
Some problems: Mobility 25.4% Self-care 14.2% Usual activities 58.6% Pain/discomfort 52.0% Anxiety/depression 63.5%  EQ-VAS 65.1 (SD 23.2) 
   
Konig et al 2009  Germany 
389 patients with anxiety disorder from 46 GP practices. 23 practices allocated intervention – training - group (n=201), and 23 to control group usual care (n=213) 
EQ-5D UK EQ-VAS  PHQ-D BAI BDI-II  
  No significant differences between control and intervention group.  BAI, BDI also showed no significant differences. 
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Konig et al 2010  Germany 
389 patients with anxiety disorder EQ-5D UK EQ-VAS WHO-QoL-BREF BSQ ACQ BAI BDI-II MI (MIA and MIB) 
Some problems for  Anxiety/Dep 77.4% Pain 71.5% Usual activities 40.8% Mobility 23% Self care 3.9% 21% of sample reported 11122 VAS: Mean (median) was 63.8 (70)  EQ5D: Mean (median) 0.66 (0.73)  1% reported 1.0 on VAS, 11.6% on EQ5D.  Problems in all dimensions reported more frequently than German population.  
At baseline. EQ-5D correlated 0.7 with physical health WHO-QoL, 0.5 with mental health WHO-QoL, 0.58 overall WHO-QoL. -0.58 with BAI, -0.54 with BDI-II 0.4 and below for BSQ, ACQ, MIA, MIB.  Almost all EQ-5D dimensions response levels were associated with significant differences in scores of WHO-QoL domains and measures of psychopathology.  Those with no problems on anxiety have a mean BAI score of 23.7, those with some problems a score of 9.2 giving an ES d = 1.53. Also strongly associated with mental health WHOQoL d = 1.44 and BDI-II d=1.52   
More anxiety if BAI increased more than 0.5 of SD of BAI (n=43) Less anxiety if BAI dec > 0.5SD (n=83), others no shift (n=124)  EQ-5D, EQ-VAS, WHO-QoL, BSQ, ACQ all show significant differences between more anxiety, constant and same (t stat).  Effects size for EQ-5D -0.99 for more anxiety (more than twice that for other measures).  Effect size 0.39 for less anxiety. SRM -0.54 for more anxiety EQ-5D again higher than other measures. 0.46 for less anxiety (BSQ -0.72, WHO-QoL 0.35).   
Ceiling effect of EQ-5D not pronounced.  Missing items on EQ5D described and only complete scores used. 
Lamers 2006  Part of RCT in the Netherlands 
Patients aged 18-65 with a diagnosis of a major depressive disorder, dysthymic disorder, panic disorder, social phobia, 
ED-5D SF-36  At baseline more respondents report having no limitations on the EQ-5D compared to the SF-6D. e.g. 78% no mobility problems and 93.5% no self-care problems 
Comparing SCL subgroups  Both measures show expected pattern, EQ-5D shows large drop in utility in most severe quartile – not found in SF-6D. SD greater in EQ-5D. Difference between mean and median greater for EQ-5D. 
Mean EQ-5D utilities increased from 0.513 to 0.680 at 1.5 years and SF-6D from 0.577 to 0.701. Mean improvement in EQ-5D utilities was lower than for SF-6D in the low severity group and higher for the 2 subgroups with highest severity. Mean improvement in EQ-5D 
EQ-5D gives larger health gains – would be translated into lower cost-utility ratios, especially for high severity sub-groups.  
 47 
generalised anxiety (classified by DSM-IV)  
according to EQ-5D BUT only 18% no limitations in physical functioning in SF-6D. e.g. 65% report 4/5 out 5 for mental health SF-6D only 33% 3/3 for EQ-5D.  Mean scores EQ-5D 0.518 (SD .29) SF-6D 0.575 (SD .10) Median EQ-5d 0.689 SF-6D 0.567 
 increased with increased severity. The SD of differences were lower for SF-6D resulting in SRMs for SF-6D that were at least twice as high as those for EQ-5D for all severity groups.  At 1.5 year follow up SRM was 0.466 for EQ-5D and 0.833 for SF-6D.   
Missing items on outcome measures not discussed 
Mann et al 2009  UK 
114 patients with depression participating in RCT on collaborative care (MMD according to SCID), Mean age 42.5, 77% female.   
SCID PHQ-9 SF-6D EQ-5D  PHQ-9 score Mild (5-9) Moderate (10-14) Mod. Severe (15-19) Severe (20-27) 
More patients responded no problems on EQ-5D than SF-6D.  Level 1: EQ-5D  Mobility 73% Self-Care 83.8% Usual activities 24.3% Pain: 35.8% Anxiety/dep: 5.5%  Level 1: SF-6D Physical: 27.9 Role limit: 1.8 Social funct: 10.1 Pain: 22.3 
EQ-5D correlated -0.451 with PHQ-9 at baseline and -0.638 at 3 month follow up  SF-6D correlated -0.351 with PHQ-9 at baseline and -0.833 at 3 month follow up.  EQ-5D Mild 0.645 (SD 0.23) Moderate 0.656 (SD 0.21) Mod severe 0.558 (SD 0.27) Severe 0.337 (SD 0.29)  SF-6D Mild 0.642 (SD 0.09) Moderate 0.601 (SD 0.09) Mod severe 0.548 (SD 0.07) Severe 0.544 (SD 0.06) 
Change from baseline EQ-5D increase 0.147 (change in median scores 0.069) SF-6D increased 0.082 (change in median scores 0.07) Both significant  62% assessed as in remission at follow-up according to SCID Remission at follow up: EQ-5D 0.759 (SD 0.25), SF-6D 0.707 (0.12) MDD at follow up: EQ-5D 0.506 (0.37), SF-6D 0.550 (0.09).  Mean improvement between baseline of overall study population and follow up utility 
Describes direct TTO or SG with patients with depression as “impractical” (p574)  Despite reporting more problems with SF-6D, EQ-5D shows greater change – may arise due to differences in valuation, at low end EQ-5D much lower. 
 48 
Mental: 0 Vitality: 1.8  Highest level mental health EQ-5D: 5.5/65.1/29.4 SF-6D: 0/1.8/11.6/54.5/32.1  86.6% of patients reported feeling tense / downhearted or low most or all of the time in the SF-6D but only 29.4% reported extreme problem with anxiety and depression on EQ-5D  Suggests more people reporting problems, and severe problems with SF-6D. SF-6D descriptors are “feelings” compared to anxiety / depression which “may be perceived as directly related to mental disorders” 
  for those with remission was EQ-5D 0.243, SF-6D 0.140.   EQ-5D showed larger health gains at follow up for all patients, and for those in remission.  
 49 
(p574)  57.1 report highest level on vitality. No comparable measure for EQ-5D.  Mittal et al 2006  USA 
324 veterans receiving primary care for depression (score 12 or more on PHQ). Mean age 59.8, 9% female. 
MINI SCL-20, (symptom checklist to identify depression severity)  SF-12v QWB-SA (utility score from published weights – Kaplan et al 1997) Duke social support and stress scale 
69% were comorbid with anxiety disorder 58% GAD 29% PTSD 11% Panic disorder  Mean QWB-SA was 0.39 (SD 0.11) 
Regression analysis found that GAD and PTSD independently predicted QWB-SA but panic disorder was not significant. 
 Missing data (2%) were impute, sensitivity analysis dropped missing data found similar results. 
Mychaskiw et al, 2008  USA  Abstract only 
374 non-depressed patients with GAD treated with pregabalin, venlafaxine-XR or placebo  
EQ-5D UK HAM-A  EQ-5D scores decreased as anxiety symptom severity increased.  Normal (HADS 0-7) 0.83 Mild (HADS 8-10) 0.78 Moderate (HADS 11-14) 0.60 Severe (HADS 15-21) 0.30 
Those achieving  Functional remission at 8 weeks (SDS < 5): EQ-5D 0.87, those not in remission: EQ-5D 0.61  Symptomatic remission at 8 weeks HAMA score 7: Remission EQ-5D 
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n at endpoint ranged from 323 to 360. All significant except normal versus mild.   
0.84, No remission EQ-5D 0.60 HAMA score 10: Remission EQ-5D 0.83, No remission EQ-5D 0.57 Petrou et al 2009  UK 
623 women in an RCT of postnatal support. 1046 declined. 312 allocated to control group receiving usual care. 311 offered 10 visits community postnatal support worker. 493 had complete data  Aged >=17  given birth to live baby.  
EQ-5D SF-6D EPDS  Self-rated (SR) health status (excellent, v. good, good, fair, poor)  Taken six months postpartum  
Mean  EQ-5D 0.861 SD 0.181 (95CI 0.844 – 0.877)  SF-6D 0.809 SD 0.140 (CI 0.796-0.822) (significantly different from EQ-5D). Median  EQ-5D 0.848 (IQR 0.796-1)  SF-6D 0.830 (IQR 0.706-0.938)  Minimum EQ-5D -0.077  Minimum SF-6D 0.374 177 women (35.9%) had EQ-5D of 1.0 and SF-6D of < 1 (29.2% and 34.1% identifying problems with mental health and vitality respectively).  Only 1 women had 
Both show monotonically decreasing scores in line with SR health status.   Relative efficiency statistic – how well can they detect differences in SR health status and EPDS. Ratio of the square of the t-statistic of the comparator instrument over the square of the t statistic of the reference instrument. Found SF-6D more efficient by 29% to 423.6%. When sample restricted (dropped 12 with low EQ-5D) SF-6D still more efficient. Also more efficient using EPDS profiles (between 129.8% and 161.7%).  Receiver operating characteristics (ROC) curves find area under curve greater for SF-6D hence same conclusion – SF-6D better at discriminating. But all but one analysis differences not significant. 
 Why 1. SF-6D taps into broader aspects of health and QOL 2. SF-6D greater number of response items – possibly greater sensitivity 3. Wording on SF-6D, which includes positive and negative items gives greater sensitive to maternal health 4. Longer time frame (past 4 weeks) v EQ-5D which is today, might increase sensitivity.  Missing items on outcome measures not discussed 
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SF-6D of 1 and identified moderate pain/discomfort on EQ-5D.  No differences in EQ-5D by demographic characteristics. Peveler et al, 2005  UK  RCT to receive a TCA or SSRI or lofepramine. 
Of 388 patients with new episode of depression referred to study 67.3% female, mean age 42.5. n=327 randomised 
EQ-5D HAD-D CIS-R PROQSY SF-36  Depression free week 
  EQ-5D of 3 groups showed improvement of about 20 points, most of which occurred in first 3 months.  Baseline (n=261) EQ-5D 0.5586 (SD 0.275) Month 2 (n=172) EQ-5D 0.763 (SD 0.195) Month 12 (n=162) EQ-5D 0.777 (SD.194) No sig. differences between 3 groups. 
 
Pyne et al 2010  USA  RCT rural telemedicine-based collaborative care for depression vs usual care 
395 primary care patients screened positive for depression using PHQ-9, 360 completed 6 month follow up, 335 completed 12 month. Excluded schizophrenia, suicide intention, 
SF-6D from SF-12 QWB Depression free days 
Baseline SF-6D  Usual care (n=179) 0.53 (SD 0.12) Intervention (n=141) 0.54 (SD 0.14)  Baseline QWB Usual care (n=179) 0.42 (SD 0.11) Intervention (n=141) 
 Depression free days find no significant differences QWB showed no difference  SF-6D showed sig. difference between intervention and usual care different. (ICER $85,634/QALY)   
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 pregnancy, substance dependence, bipolar 
0.43 (SD 0.13) 
Pyne et al 1997  US 
100 patients with primary diagnosis of major depression, 60 outpatients and 40 inpatients (from Veteran Affairs Medical Centre). Control group (n=61) identified by VA medical centre staff, without current or past diagnosis of mental illness  Diagnosed by SADS or SCID criteria  Patients: mean age 48.5, 18% female Control group: mean age 47.4, 1.6% female  
BDI HRSD QWB  QWB scale Control group: 0.813 (n=61)  Rated using HRSD (n=95) Mild: 0.676 Moderate: 0.645 Severe: 0.554  Rated using BDI (n=87) Mild: 0.698 Moderate: 0.643 Severe: 0.597  Regression analysis found no sig. relationship with QWB and age, gender, or family history of mental illness  BDI and HRSD strong predictors of QWB, even when controlling for presence of comorbid axis III diagnosis 
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Reed 09  FINDER  12 European countries 
Patients (>= 18) with clinical depression enrolled prior to commencing antidepressant treatment.   Of 3468 at baseline, 343 had no follow up data, 271 data at 3 months only, 2854 had 3 & 6 months.  Age not given. Gender not given. 
EQ-5D EQ-VAS  SF36,  HADS-D, HADS-A,  SSI-28-item Somatic Symptom Inventory, Pain VAS  
Baseline EQ-5D 0.44 and 44.8 VAS, showed improvement at 3 & 6 months (other data on a graph)  
Regression analysis found significant negative relationship between number of previous depressive episodes and duration of current episode. Also negatively related to somatic symptoms and VAS pain. 
 Age, country and SSI-somatic score at baseline related to probability of dropout.  Missing items on outcome measures not discussed 
Revicki et al 2008  USA  KPNW study 
297 patients with GAD, 72% female, mean age 47.6  HAM-A score Asymp. <= 9 Mild 10-15 Moderate 16-24 Severe >=25 
SCID SIGH-A GAD-Q-IV, Q-LES-Q-SF, PHQ, SF-12, HUI2, HUI3 
Baseline  HAM-A score 16.7 HUI2 0.54 (SD 0.2) HUI3 0.46 (SD 0.3) SF-6D 0.62 (SD 0.1)  
Correlations with HAM-A HUI2 -0.52 HUI2 -0.54 SF-6D -0.52  Correlations with GAD-Q-IV HUI2 -0.43 HUI2 -0.44 SF-6D -0.38  Correlations with PHQ HUI2 -0.52 HUI2 -0.57 SF-6D -0.64  Suggest utility measures are 
Presents outcomes by HRQL at 3 months by anxiety severity – shows similar picture. HUI2 and HUI3 not able to sig. distinguish between asymptomatic and mild groups.  
Authors note that the greater sensitivity of HUI3 compared to HUI2 may be due to content of the emotional domain which focuses on happiness and depression rather than worry and anxiety.  
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most strongly correlated with depression scores.  HUI2 Asymp. 0.70 (SD 0.2) Mild 0.59 (SD 0.2) Moderate 0.5 (SD 0.2) Severe 0.36 (SD 0.2) HUI3 Asymp. 0.68 (SD 0.2) Mild 0.54 (SD 0.3) Moderate 0.39 (SD 0.3) Severe 0.17 (SD 0.3)  SF-6D Asymp. 0.72 (SD 0.1) Mild 0.64 (SD 0.1) Moderate 0.60 (SD 0.1) Severe 0.53 (SD 0.1)  HUI3 most sensitive to increased anxiety All compare favourably to other clinical measures.  All differences significant  Regression analysis found that symptom measures explained 38% of variance of HUI2, 42% of HUI3 and 46% of SF-6D 
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Saarni 2007  Finland Population survey, aged 30 and over. Included assessment of 12-month prevalence of depressive anxiety or alcohol disorders (DSM-IV).    
EQ-5D UK 15D measure with Finnish valuations  Munich version of the Composite International Diagnostic Interview (M-CICI) used to asses 12-month prevalence of depressive, anxiety or alcohol use disorders    
5219 had data on EQ5D and M-CIDI,    65% of sample had EQ5D and M-CIDI data. 
47% scored full health on EQ-5D (30%) of those with psychiatric disorder.   Unadjusted scores for population were 0.83 for EQ5D and 0.72 for those with any psychiatric diagnosis.   Controlling for socio-economic status, somatic comorbidity and psychiatric comorbidity Depressive disorders reduces EQ-5D -0.091 (CI-0.114 to -0.068) Anxiety disorders reduced EQ-5D -0.114 (-0.144 to -0.085) GAD reduced EQ-5D -0.110 (-0.158 to -0.061) MDD -0.058 (-0.079 to -0.036) Dysthymia -0.122 (-0.167 to -0.077) Panic disorder NS Social phobia -0.102 (-0.166 to -0.039) Agoraphobia NS 
 Only fully completed EQ-5D were included.  For 15D only those with 12 more responses included, and missing data were imputed. 
Sapin 2004  France Outpatient population consulting at GP for new episode of major depressive disorder (MDD) 
Patient reported: EQ-5D SF-36 QLDS  Clinical/phy
At baseline mean EQ-5D was 0.33 (+/-0.25) range -0.59 to 0.85. 8% had EQ-5D worst than death. Baseline – no difficulties in 
Significant differences in EQ-5D by disease severity level (CGI-s) e.g. at baseline 0.12 difference between slightly/moderately ill and markedly ill. Slightly ill and markedly ill scores differed by 
4 weeks mean EQ-5D 0.68 (+/-0.24 range -0.11-1)  8 weeks mean EQ-5D 0.78 (+/- 0.21 range -0.08 to 1) Extreme difficulties on anxiety & depression was 77.9% at baseline moved to 9.3% at D56. 
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according to DSM-IV, aged 18 and over, not treated with any antidepressants prior to inclusion.  Exclusion Symptoms suggests schizophrenia or psychotic symptoms  
sician reported: MADRS  CGI-S  
mobility 73.5%, self-care 82.3% usual activities 24.8% pain discomfort 23.9%, anxiety depression 0.9%.   MADRS score at D56 <= 12 classed as remitters others as non-remitters  If decrease of at least 50% from baseline classed as responder, others non-responders  Responder remitters Responder non-remitters Non-responder 
0.3.   Correlation between SF-36 MHC and EQ-5D was 0.49, 0.56 and 0.63 at baseline, D28 and D56 respectively.  Correlations between QLDS range -0.43 to -0.68 at D56.  EQ-5D by response group at baseline, D28 and D56 Non-responders 0.30 (SD 0.27), 0.54 (SD 0.30), 0.58 (SD 0.28)  Responder-remitters 0.35 (SD 0.24), 0.76 (SD 0.18), 0.85 (SD 0.13)  Responder-non-remitters 0.21 (SD0.25), 0.54 (SD 0.26), 0.72 (SD 0.20) 
  Regression analysis dependent variable the difference (baseline – assessment) EQ-5D independent other measures explained 40% of the variation in EQ-5D.  
Serfaty et al, 2009  UK  RCT of CBT for older people with depression 
N=204 Age 65 or older, with depression screened by 15-item geriatric depression scale or BDI-ii score 14 or more. Mean age 74.1, 79.4% female  
 BDI-II BAI-II SFQ EQ-5D (no reference to scoring system)  
  CBT: EQ-5D: Baseline: 0.50 (032) n=70 4 months: 0.53 (0.34) n=61 10 months: 0.54 (0.33) n=56  Taking Control treatment: EQ-5D Baseline: 0.52 (031) n=67 4 months: 0.55 (0.39) n=57 10 months: 0.52 (0.32) n=53  
Missing data were imputed. 
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Measurement: baseline, 4 months, 10 months  
Treatment as usual: EQ-5D Baseline: 0.46 (0.29) n=67 4 months: 0.47 (0.38) n=55 10 months: 0.52 (0.31) n=50   CBT: BDI-II Baseline: 27.3 4 months: 18.4 10 months: 18.3  TAU: BDI-II Baseline: 27.7 4 months: 20.3 10 months: 20.8 Significant difference in improvement in CBT versus TAU for BDI-II  When adjusted for baseline BDI-ii GP numbers, baseline outcome value, time period, BDI-II significantly better than TAU or CBT. EQ-5D found CBT significantly better than TC but not significantly different to TAU. Sobocki et al, 2007  Sweden 
Subjects attending GP at 56 centres in Sweden. N=447. Baseline data on n=394.  
EQ-5D UK  CGI-S (1-7) (Severity) CGI-I (Improv.)  
24% had mild depression, 69% moderate (CGI-S score of 4 or more), 16% severe (CGI-S score 5-7) 
Sig. differences in EQ-5D by disease severity as assessed by CGI-S Mild  0.6 (0.54-0.65)  Moderate 0.46 (0.30-0.48), Severe 0.27 (0.21-0.34) 
Baseline EQ-5D 0.47 (0.44-0.5) range 0-1. (n=394) First follow up visit EQ-5D 0.60 (0.57-0.62) (n=378) At about 6 months EQ-5D 0.66 (0.53-0.75) (n=28) 
Numbers in study at 6 months very low. 
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Mean age 47, 67% female. Aged > 18 diagnosis of depression (according to centres practice), initiating new treatment with antidepressants  
 59% had a least one comorbidity 56% physical comorbidities 9% psychiatric.  Cut off EQ-5D at zero but 8% rated as worst than dead. (authors note that recalculating with SWD allowed does not substantially effect the results). 
 Sig. difference between mild/moderate but not between moderate and severe.  Pattern similar at follow up (0.76/0.65/0.52)  Regression analysis – explanatory variables explained 23% of EQ-5D variation. Demographic variables not significant. 
At last follow up visit EQ-5D 0.69  (0.67-0.72), corresponding to increase in utility of 0.23 (p< 0.0001)  EQ-5D increased 40 to 63 at about 6 months.  Increase by severity classification Mild: 0.16 (0.11-0.23) Moderate: 0.22 (0.18-0.26) Severe: 0.35 (0.25-0.44) 
Stein et al, 2005  USA  CCAP trial 
N=480 outpatients with anxiety disorder, 63% female 
SF-6D from the SF-12 WHO Disability scale 
Adjusting for covariates any anxiety disorder lowered utility values by -0.122 and co-morbid major depression by -0.087.   Adjusting for covariates (comorbidities, socio-economic factors) utility primary care patients without anxiety or depressive disorder 
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0.80 (0.78-0.82): With anxiety disorder alone 0.68 (0.66-0.70), with depressive disorder alone 0.72 (0.66-0.79), both 0.59 (0.57-0.61)  van Straten et al, 2008  The Netherlands 
N=213 recruited via media N=107 web self help intervention for depression, anxiety and work-related stress N=106 control group 
EQ-5D CES-D MDI HADS SCL-A MBI, work related stress – 3 subscales. 
  EQ-5D  Control Pre:0.61 Post: 0.66 Intervention all: Pre 0.62 Post 0.73 Intervention complete: Pre 0.63 Post 0.8  Effect size (Cohens d)  All (n=107), course completers (n=59) CES-D 0.5 (0.22-0.79), 0.67 (0.32-1.02) MDI 0.33 (0.03-0.63), 0.56 (0.22-0.9) SCL-A 0.42 (0.14-0.70), 0.51 (0.18-0.84) EQ-5D 0.31 (0.03-0.60), 0.44 (0.11-0.77) HADS 0.33 (0.04-0.61), 0.48 (0.15-0.82)  MBI not sig. 
Missing data were imputed by regression analysis 
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Supina et al 2007  Canada 
Alberta Mental Health Survey, stratified random sample. Sample size n=5,410 (77% return), n=5,383 successful data. Mean age 40.8. Female 61.2%  
EQ-5D EQ-VAS MINI MDE (recurrent and current) alone 2.6% Anxiety disorders only 11.2% MDE and anxiety 5.2% Neither 80.9%    
Anxiety only (n=601) EQ-5D 0.84 (0.83-0.85). EQ-VAS 76.68 MDE only (n=140) 0.83 (0.81-0.85), VAS 70.82 Anxiety and MDE (n=280) 0.70 (0.69-0.72), VAS 64.17 Neither (n=4338) 0.92 (0.91-0.92), VAS 84.68  
  
Swan et al, 2004.  RCT of Coping with Depression (CWD) course.  UK 
Inclusion: Primary diagnosis of chronic or recurrent depressive disorder; current depressive episode of at least moderate severity (ICD=10 F32.1-F32.2, F33.1-F33.2); inadequate or poor response to previous treatments. Aged 18-65  N=76 entrants, 31 completed CWD, n= 26 (34%) attended 
BDI-II. BSI which generates the GSI EQ-5D (no reference to scoring system)  Allocated to worse, unchanged, improved or recovered based on BDI-II and GSI 
Baseline EQ-5D 0.44 (SD 0.41, range -0.24 to 1.0) (n=76)  EQ-5D (n=26) Baseline: 0.49 (SE 0.07) (0.34-0.64) Week 12: 0.65 (SE 0.06) (0.52-0.79) Week 26 0.68 (SE 0.06 (0.55-0.82) Significant improvement in BDI and GSI (baseline- 12; baseline-26). 
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follow up. No differences in clinical or demographic characteristics between completers and drop outs. Wells et al 2007  Partners in Care data USA 
Patients with recent depressive disorder or sub-threshold depression (current depressive symptoms but no disorder)  Usual care n= 214 Quality improvement n=532 (of which Medication n=249 Therapy n=283)  Usual care: mean age 43, 71% female Quality improvement 44, 77% female 
SF-12 with weights derived from a convenience sample of primary care patients using SG (see Lenert et al 2000 above) 
  Incremental effect of quality improvement over usual care  For depressive disorder (n=746) Days of depression burden over 24 months -46 (95% CI -84; 8) p = 0.02  Days of employment over 24 months 23 (5 41) p= 0.1  QALY gain 0.02 (0 to 0.4) p=0.1  For sub-threshold (n=502) QALY gain 0.02 (0;0.4) p=0.06  Days depression burden -31 (-71;9) p= 0.13  Days employment 15 (-1;31) p = 0.07  
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Zivin et al 2008  USA 
n=87,797 Veterans, mean age 60, 10% female  Identified from VA depression registry and VA outpatients  n=58,442 with depression 
SF-6D from the SF-12 VA with depression Utility 0.57 (SD 0.13)  VA without depression 0.63 (SD 0.14) 
   
 
 
